X
[{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cobra Biologics successfully completes key milestone in CombiGene\u2019s epilepsy project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cobra Biologics"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cobra Biologics"},{"orgOrder":0,"company":"Locate Bio","sponsor":"Mercia Asset Management","pharmaFlowCategory":"D","amount":"$13.7 million","upfrontCash":"Undisclosed","newsHeadline":"Locate Bio Closes \u00a310 million Funding Round","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Locate Bio"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Solutions Forms New Partnerships With Three Biotechnology Companies","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Oxford Biomedica"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Oxford Biomedica Solutions will provide its full platform offering to support the new partners’ pre-clinical gene therapy programmes, which cover development programmes including CNS, autoimmune disease, oncology, muscular disorder, and rare metabolic disease.
Lead Product(s):
Undisclosed
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
December 14, 2022
Details:
The funding will be used to advance Locate Bio’s proprietary pipeline, including its lead product called LDGraft, a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.
Lead Product(s):
rhBMP-2
Therapeutic Area: Neurology
Product Name: LDGraft
Highest Development Status: Undisclosed
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Mercia Asset Management
Deal Size: $13.7 million
Upfront Cash: Undisclosed
Deal Type: Funding
September 03, 2021
Details:
Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.
Lead Product(s):
DNA plasmids
Therapeutic Area: Neurology
Product Name: CG01
Highest Development Status: Undisclosed
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
CombiGene AB
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
July 13, 2020
Details:
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.
Lead Product(s):
CG01
Therapeutic Area: Neurology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 02, 2020